Cellectis S.A. 2016 Annual Report (Form 20-F) Summary
Business Context and Reporting Period
Company: Cellectis S.A., a French biopharmaceutical and agricultural biotechnology company.
Reporting Period: Fiscal year ended December 31, 2016.
Business Model: Cellectis operates two primary segments: Therapeutics, focused on developing allogeneic CAR T-cell immunotherapies for cancer using proprietary TALEN gene-editing technology; and Plants (via subsidiary Calyxt), focused on developing gene-edited crops for agricultural biotechnology. The company has no approved products for commercial sale and relies on strategic alliances (Servier, Pfizer) and equity financing to fund operations.
Key Financial Metrics (Year Ended Dec 31, 2016)
| Metric | 2016 (€ millions) | 2016 ($ millions) |
|---|---|---|
| Revenues and Other Income | 51.0 | 53.8 |
| Operating Expenses | (111.8) | (117.8) |
| Research & Development | (70.9) | (74.7) |
| Selling, General & Administrative | (39.2) | (41.4) |
| Royalty Expenses | (1.6) | (1.7) |
| Operating Loss | (60.8) | (64.1) |
| Net Loss (Attributable to Shareholders) | (60.8) | (64.1) |
| Adjusted Net Loss (Non-GAAP) | (7.8) | (8.2) |
| Cash and Cash Equivalents | 276.2 | 291.2 |
| Total Assets | 314.4 | 331.4 |
| Total Shareholders' Equity | 260.6 | 274.7 |
Note: USD figures are translated at the ECB rate of €1.00 = $1.0541 as of Dec 31, 2016. Adjusted Net Loss excludes non-cash stock-based compensation of €53.0 million.
Material Changes vs. Prior Period (2015)
- Revenue Decline: Total revenues decreased by approximately 9.5% from €56.4 million in 2015 to €51.0 million in 2016. This was primarily due to lower collaboration payments received from Pfizer and Servier in 2016 compared to 2015.
- Increased Operating Loss: The operating loss widened significantly from €27.9 million in 2015 to €60.8 million in 2016. This was driven by a 35% increase in R&D expenses (€52.4M to €70.9M) and a 44% increase in SG&A expenses (€27.2M to €39.2M).
- Stock-Based Compensation: Non-cash stock-based compensation expense surged to €53.0 million in 2016 from €30.1 million in 2015, significantly impacting the GAAP net loss.
- Liquidity: Cash and cash equivalents decreased by approximately €38 million (from €314.2M to €276.2M) due to the net burn rate, though the company maintains a strong cash position.
Guidance, Outlook, and Management Commentary
- Clinical Progress:
- UCART19: Servier (collaborator) commenced Phase I clinical studies in the UK in June 2016. Preliminary data from compassionate use and early clinical patients were presented in late 2016. FDA approval to extend the Phase I study in the US was announced in March 2017.
- UCART123: Cellectis received FDA approval in February 2017 to commence Phase I clinical studies for Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). IRB approvals at Weill Cornell and MD Anderson were pending as of the filing date.
- Financial Outlook: Management expects to continue incurring significant losses and increasing cash utilization in the near term as clinical studies commence and R&D expands. The company believes its cash position (€276 million as of Dec 31, 2016) is sufficient to fund operations through 2019.
- Risks and Contingencies:
- Regulatory Uncertainty: Significant risks exist regarding the approval of gene-edited products by the FDA and EMA, including potential delays in IRB approvals for clinical trials.
- Collaboration Dependence: Future revenue is heavily dependent on milestone payments and royalties from Servier and Pfizer, which are contingent on successful clinical development.
- Manufacturing: Reliance on third-party contract manufacturers (CMOs) for clinical and future commercial supply introduces supply chain risks.
- Intellectual Property: The company faces potential patent challenges and litigation risks common in the biotechnology sector.
Key Facts for Investor Verification
- Cash Runway: Verify the company's assertion that €276 million in cash is sufficient to fund operations through 2019, considering the accelerating burn rate and upcoming clinical trial costs.
- Clinical Trial Initiation: Confirm the status of IRB approvals at Weill Cornell and MD Anderson Cancer Center required to commence the UCART123 Phase I trials approved by the FDA in February 2017.
- Collaboration Milestones: Monitor the progress of the UCART19 trials sponsored by Servier/Pfizer, as future revenue is tied to specific development and commercial milestones under these agreements.
- Non-GAAP Adjustments: Review the reconciliation of Net Loss to Adjusted Net Loss, noting that the €53 million stock-based compensation adjustment significantly masks the GAAP loss.
- Regulatory Pathway: Assess the evolving regulatory landscape for gene-edited therapies (both cell therapy and agricultural crops) in the US and EU, as this impacts the timeline for commercialization.